| Literature DB >> 27099234 |
Nilgun Tasdemir1, Ana Banito2, Jae-Seok Roe3, Direna Alonso-Curbelo2, Matthew Camiolo4, Darjus F Tschaharganeh2, Chun-Hao Huang5, Ozlem Aksoy1, Jessica E Bolden2, Chi-Chao Chen5, Myles Fennell2, Vishal Thapar2, Agustin Chicas2, Christopher R Vakoc6, Scott W Lowe7.
Abstract
UNLABELLED: Oncogene-induced senescence is a potent barrier to tumorigenesis that limits cellular expansion following certain oncogenic events. Senescent cells display a repressive chromatin configuration thought to stably silence proliferation-promoting genes while simultaneously activating an unusual form of immune surveillance involving a secretory program referred to as the senescence-associated secretory phenotype (SASP). Here, we demonstrate that senescence also involves a global remodeling of the enhancer landscape with recruitment of the chromatin reader BRD4 to newly activated super-enhancers adjacent to key SASP genes. Transcriptional profiling and functional studies indicate that BRD4 is required for the SASP and downstream paracrine signaling. Consequently, BRD4 inhibition disrupts immune cell-mediated targeting and elimination of premalignant senescent cells in vitro and in vivo Our results identify a critical role for BRD4-bound super-enhancers in senescence immune surveillance and in the proper execution of a tumor-suppressive program. SIGNIFICANCE: This study reveals how cells undergoing oncogene-induced senescence acquire a distinctive enhancer landscape that includes formation of super-enhancers adjacent to immune-modulatory genes required for paracrine immune activation. This process links BRD4 and super-enhancers to a tumor-suppressive immune surveillance program that can be disrupted by small molecule inhibitors of the bromo and extra terminal domain family of proteins. Cancer Discov; 6(6); 612-29. ©2016 AACR.See related commentary by Vizioli and Adams, p. 576This article is highlighted in the In This Issue feature, p. 561. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27099234 PMCID: PMC4893996 DOI: 10.1158/2159-8290.CD-16-0217
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397